Compare SABS & OPBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | OPBK |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 210.6M |
| IPO Year | N/A | 2018 |
| Metric | SABS | OPBK |
|---|---|---|
| Price | $3.88 | $14.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.75 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 996.7K | 28.5K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.73% |
| EPS Growth | N/A | ★ 23.74 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $3,204,000.00 |
| Revenue This Year | N/A | $16.07 |
| Revenue Next Year | N/A | $11.60 |
| P/E Ratio | ★ N/A | $29.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $11.57 |
| 52 Week High | $6.60 | $15.27 |
| Indicator | SABS | OPBK |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 50.96 |
| Support Level | $3.54 | $13.65 |
| Resistance Level | $4.11 | $14.89 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 38.58 | 44.00 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.